

Serious Hazards of Transfusion (SHOT)

Non-medical authorisation course



Learning objectives:

By the end of this session with the additional of the E learning delegates will be able to:


- 🔥 Describe the role of SHOT in the UK haemovigilance system, including its function in collecting, analysing, and disseminating transfusion-related incident data.
- 🔥 Understand the role of Non-Medical Authorisation (NMA) practitioners in haemovigilance, including their contribution to transfusion safety, clinical decision-making
- 🔥 Apply SHOT data to clinical practice by analysing case studies that illustrate key transfusion risks such as TACO, Delays and IBCT, and identifying lessons learned to improve patient safety.

Join the Vevox session

Go to **vevox.app**

Enter the session ID: **144-502-585**

Or scan the QR code





What was the total number of reports submitted to SHOT in 2024?

4,250

0%

4,972

0%

5,033

0%

5,500

0%



What was the total number of reports submitted to SHOT in 2024?




RESULTS SLIDE

Beyond Incidents: ACE Reports

- SHOT also captures Acknowledging Continuing Excellence (ACE) reports
- Highlights good practice and promotes a Safety-II approach
- Resources and learning tools available via the SHOT website




Transfusion related deaths in 2024 with imputability (n= 59) ↑↑



Deaths related to transfusion 2010-2024 (n=379)

by SHOT category



Important to note:

TACO and **delays** are the most common causes of transfusion-related deaths in the UK year on year



Absolute number of deaths reported have increased post COVID with a further steep increase in 2024 - this could be due to multiple factors

Deaths reported

2013 = 0.80 per 100,000 components issued


2024 = 2.68 per 100,000 components issued

Delayed transfusions by year 2011-2024



Laboratory errors resulting in transfusion delays n=120 (was 56 in 2023) ↑↑↑

Laboratory errors (n=120)



Key themes:

- Communication issues
- Problems with handover
- Availability of blood components

Transfusion: A Life-Saving Therapy — But Not Without Risk

Key Considerations

- Transfusion is not risk-free — even in well-functioning systems.
- The safest transfusion is the one not given — but only *if* the patient can safely go without it.
- Clinical judgement is vital: withholding transfusion must never result in preventable harm or death.


Vulnerable Groups

- Adults: Especially those with comorbidities or undergoing complex procedures.
- Paediatrics: Smaller blood volumes increase sensitivity to errors and reactions.
- Sickle Cell Patients:
 - Higher transfusion exposure.
 - Increased risk of alloimmunisation, delayed haemolytic reactions, and hyperhaemolysis.
 - Require tailored transfusion strategies and vigilant monitoring.

Safe Practice Principles

- Balance benefit vs risk for every transfusion decision.
- Use alternatives where appropriate (e.g. iron therapy, cell salvage).
- Ensure informed consent includes discussion of risks.
- Prioritise haemovigilance and continuous improvement.

The A-E Decision Tree to facilitate decision making in transfusion



The A-E Decision Tree to facilitate decision making in transfusion


- A** Assess patient
Any avoidable blood loss
(frequent, unnecessary tests/interventions)
- B** Blood results (all) reviewed including trends – valid and reliable?
Best treatment option – is transfusion the best treatment option? If yes, what components needed, how many, what order and any specific requirements needed?
- C** Consent/communication (adequate patient information – both verbal and written) to patients and where appropriate to families and carers
Correctable factors to be addressed like bleeding, haematinic deficiency
- D** Do not forget other measures (vitamin K, tranexamic acid, cell salvage, etc)
Do not hesitate to question colleagues regarding decisions made and ask for rationale
Do not forget to document in patient's notes and in discharge summaries
- E** Ensure timely communications to laboratory- need to be clear, concise and accurate
Ensure all relevant transfusion checklists including TACO risk assessment and actions arising thereafter have been completed
Evidence based decisions made weighing risks, benefits and options available
Ensure patient receives adequate post-transfusion information if transfusion given as a day case

**CHILDREN ARE NOT
SMALL ADULTS -
CHECK PAEDIATRICIAN
THRESHOLD BEFORE
TRANSFUSION**




SHOT
Serious Hazards
of Transfusion

SHOT paediatric summary data 2024; n=202



Paediatric major morbidity by SHOT reporting category 2011-2024



SHOT reports: Error common themes

Patient identification




Communication errors




Over (or under transfusion): Prescribing and administration errors



Failure to meet special requirements



Neonatal use of Adult O D Negative units



Acting on erroneous results



Laboratory errors; Neonatal compatibility and testing



Delays in transfusion: Massive haemorrhage



Case Study





Patient Profile: Mrs. A, 37 years old, at 30 weeks gestation, presenting with shortness of breath, fatigue, and palpitations.



Medical History: Known coronary heart disease with previous stent placement; currently on low-dose aspirin.



Pre-transfusion Findings: Haemoglobin critically low at 55 g/L.



Vital Signs: Tachycardia (HR 115 bpm), hypotension (BP 95/60 mmHg), increased respiratory rate (RR 24), and SpO₂ 95% on room air.



What are your key considerations?

Has informed consent been obtained and documented?

0%

Has the risk of Transfusion-Associated Circulatory Overload (TACO)

0%

What is the transfusion strategy and any mitigations?

0%

All the above

0%



What are your key considerations?

Has informed consent been obtained and documented?

0%

Has the risk of Transfusion-Associated Circulatory Overload (TACO)

0%

What is the transfusion strategy and any mitigations?

0%

All the above



0%

RESULTS SLIDE



Which of the following is essential when obtaining informed consent for transfusion in a pregnant patient with CHD?

Only verbal consent is required

- | | | |
|--------------------------|--|----|
| <input type="checkbox"/> | Risks, benefits must be explained, tailored to her condition and alternatives if appropriate | 0% |
| <input type="checkbox"/> | Consent is not needed if MDT has agreed | 0% |
| <input type="checkbox"/> | Written consent is mandatory in all case | 0% |
| <input type="checkbox"/> | | 0% |



0/2

Join at: vevox.com

ID: 144-502-585

Preparing Results

Which of the following is essential when obtaining informed consent for transfusion in a pregnant patient with CHD?

Only verbal consent is required

- Risks, benefits must be explained, tailored to her condition and alternatives if appropriate 0%
- Consent is not needed if MDT has agreed 0%
- Written consent is mandatory in all case 0%
- 0%

RESULTS SLIDE



Serious Hazards of Transfusion



##/##

Join at: vevox.app

ID: 144-502-585

Question slide

What does the SHOT TACO Risk Assessment Tool help clinicians evaluate?

Blood group compatibility

0%

Risk of haemolytic transfusion reactions

0%

Risk of transfusion circulatory overload and mitigation strategies

0%

Need for platelet transfusion

0%



What does the SHOT TACO Risk Assessment Tool help clinicians evaluate?

Blood group compatibility

0%

Risk of haemolytic transfusion reactions

0%

Risk of transfusion circulatory overload and mitigation strategies

0%

Need for platelet transfusion

0%

RESULTS SLIDE



What is one recommended mitigation strategy for a patient identified as high risk for TACO?

Transfuse both units rapidly

0%

Use whole blood instead of red cells

0%

Transfuse one unit at a time with reassessment

0%

Avoid monitoring during transfusion

0%



What is one recommended mitigation strategy for a patient identified as high risk for TACO?

Transfuse both units rapidly

0%

Use whole blood instead of red cells

0%

Transfuse one unit at a time with reassessment

0%

Avoid monitoring during transfusion

0%

RESULTS SLIDE



What other consideration should be made when selecting blood components for a pregnant patient?

Use of irradiated blood

- | | |
|--|----|
| <input type="checkbox"/> | 0% |
| CMV-negative status is preferred to reduce foetal infection risk | 0% |
| <input type="checkbox"/> | 0% |
| Whole blood is preferred for volume replacement | 0% |
| <input type="checkbox"/> | 0% |
| Platelets should be given routinely in anaemia | 0% |
| <input type="checkbox"/> | 0% |



What other consideration should be made when selecting blood components for a pregnant patient?

Use of irradiated blood

<input type="checkbox"/>	0%
CMV-negative status is preferred to reduce foetal infection risk	
<input type="checkbox"/>	0%
Whole blood is preferred for volume replacement	
<input type="checkbox"/>	0%
Platelets should be given routinely in anaemia	
<input type="checkbox"/>	0%

RESULTS SLIDE

Patient review:



6 hours later you come back to review the patient



The patient has not started to received any of the red blood cell.



There was a misunderstanding regarding who should request the red cell units from the transfusion laboratory. You assumed the nurses would request the blood as this was routine practice in the clinical area where you have previously worked.



Conversely, the nurses assumed the authoriser would be requesting the blood as this was routine practice on the current ward.



##/##

Join at: vevox.com

ID: 144-502-585

Question slide

Which of the following actions would best support role clarity and prevent delays in transfusion? (tick all that apply)

Assume the same transfusion workflow applies across all wards

- | | | |
|--------------------------|--|----|
| <input type="checkbox"/> | Clarify local transfusion responsibilities during team handover | 0% |
| <input type="checkbox"/> | Use a standardised transfusion checklist or protocol | 0% |
| <input type="checkbox"/> | Wait until the patient asks about the delay | 0% |
| <input type="checkbox"/> | Clearly document who is responsible for requesting blood component | 0% |
| <input type="checkbox"/> | | 0% |



##/##

Join at: vevox.com

ID: 144-502-585

Results slide

Which of the following actions would best support role clarity and prevent delays in transfusion? (tick all that apply)

Assume the same transfusion workflow applies across all wards




<input type="checkbox"/>	Clarify local transfusion responsibilities during team handover	0%
<input type="checkbox"/>	Use a standardised transfusion checklist or protocol	0%
<input type="checkbox"/>	Wait until the patient asks about the delay	0%
<input type="checkbox"/>	Clearly document who is responsible for requesting blood component	0%
<input type="checkbox"/>		0%

RESULTS SLIDE

SHOT

Serious Hazards
of Transfusion


TACO pre-transfusion risk assessment

	Does the patient have any of the following: diagnosis of heart failure*, congestive cardiac failure (CCF), severe aortic stenosis, or moderate to severe left ventricular dysfunction?		
	Is the patient on a regular diuretic?		
	Does the patient have severe anaemia?		
	Is the patient known to have pulmonary oedema?		
	Does the patient have respiratory symptoms of undiagnosed cause?		
	Is the fluid balance clinically significantly positive?		
	Is the patient receiving intravenous fluids (or received them in the previous 24 hours)?		
	Is there any peripheral oedema?		
	Does the patient have hypoalbuminaemia?		
	Does the patient have significant renal impairment?		


Review the need for transfusion (do the benefits outweigh the risks)?	
Can the transfusion be safely deferred until the issue is investigated, treated or resolved?	
If Proceeding with Transfusion: Assign Actions TICK	
Body weight dosing for red cells	
Transfuse a single unit (red cells) and review symptoms	
Measure fluid balance	
Prophylactic diuretic prescribed	
Monitor vital signs closely, including oxygen saturation	
Name (PRINT):	
Role:	
Date:	Time (24hr):
Signature:	

*Due to the differences in adult and neonatal physiology, babies may have a different

TACO investigation guidance tool



Anaemia in a non-bleeding adult patient



The 2024 reporting year recorded **188** TACO cases which is the highest ever reported to SHOT.

A TACO pre-transfusion risk assessment should be utilised whenever possible prior to every transfusion, especially in vulnerable patients.

It is important that all TACO cases are used as a learning opportunity to prevent or mitigate TACO in other patients.

A TACO investigation guidance tool available from 'Current resources' on the SHOT website helps optimise learning from these events

Patients with severe chronic anaemia should receive only minimal red cell transfusion with the aim of alleviating symptoms as opposed to aiming for a Hb correcting to meet a target Hb level

Preventing transfusion delays in bleeding and critically anaemic patients.

Date of issue: 17-Jan-22 Reference No: SHOT/2022/001

This alert is for action by: **NHS and independent (acute and specialist) sector where transfusions are carried out.**

Access to blood components and products is a complex safety critical issue that is relevant across many departments and professions. Implementation of this alert should be coordinated by an executive leader (or equivalent role in organisations without executive boards) and supported by their designated senior leads for medical, nursing and pathology teams.

Explanation of identified safety issue:

Transfusion delays are preventable. Patients should not die or suffer harm from avoidable delays in transfusion.

The urgent provision of blood components and/or blood products is vital for life threatening bleeding and severe anaemia as described in the three situations below. A rapid, focused approach is required as delays can result in preventable death or end-organ damage.

Delays in provision and transfusion of blood during major haemorrhage have been identified repeatedly in Annual SHOT Reports¹. Delays are compounded by failure to recognise bleeding, communication failures and the presence of red cell antibodies in the patient blood sample².

Autoimmune haemolytic anaemia (AIHA) is a relatively uncommon disorder caused by autoantibodies directed against the patient's own red blood cells, with an estimated prevalence of 17:100,000 and a mortality rate of 11%^{3,4}. Urgent provision of blood may be needed for patients with severe anaemia. Laboratory testing may be complicated by the presence of the autoantibodies.

Anticoagulation is associated with an increased risk of bleeding which can be life/limb or sight threatening. Rapid reversal of anticoagulation in these cases is mandatory and delays impact patient safety. Prothrombin Complex Concentrates (PCC) are human blood products recommended for use as first line treatment for warfarin reversal (and for some other oral anticoagulants) when patients present with severe, life threatening bleeding. PCC should ideally be given within an hour once the anticoagulant reversal decision is made, particularly in patients with intracranial haemorrhage (ICH)⁵. Delays or omissions in administration can result in serious morbidity (such as expansion of an ICH) or death^{6,7}. Poor communication, patient transfer between departments, dosage calculation and perceived need for consultant approval contribute to PCC delays⁸.

Actions required

Local organisations must have:
Actions to be completed as soon as possible and no later than 15 July 2022.

1. Reviewed and updated policies and procedures to cover:
 - a. Rapid release of blood components and products for major haemorrhage, AIHA and reversal of anticoagulants.
 - b. Compliance with SHOT¹, NICE⁴ and BSH⁹ recommendations.
 - c. Agreed criteria where rapid release of PCC is acceptable without the initial approval of a haematologist.
 - d. Concessionary, rapid release of the best matched red blood cells for patients with red cell antibodies.
 - e. Criteria and pathways for laboratory escalation to a haematologist where transfusion is urgent, and the presence of antibodies might delay release of red blood cells.
 - f. Treatment of patients who refuse transfusion of blood components and/or products.
2. Reviewed, updated, and implemented training programmes to include:
 - a. Recognition of bleeding, importance of communication, processes for activation of major haemorrhage protocols and rapid access to blood components and products in clinical staff training programmes.
 - b. Major haemorrhage drills, simulations and debriefs into regular staff training activities, including clinical and laboratory teams.
 - c. Concessionary, rapid release of the best matched red blood cells for patients with red cell antibodies.
 - d. A process for recording participation and identifying dates for re-training.
 - e. Treatment of patients who refuse transfusion of blood components and/or products.
3. Implemented processes to audit and investigate all transfusion delays, using appropriate investigation tools to identify system factors for improvement.



For further detail, resources and supporting materials see: www.shot.org

For any enquiries about this alert contact: SHOT@nhs.uk



Reducing risks for transfusion-associated circulatory overload

Date of issue: 4-Apr-24 Reference No: NHPSA/2024/004/MHRA

This alert is for action by: **NHS and independent (acute and specialist) organisations where transfusions occur**

This is a safety critical and complex National Patient Safety Alert that is relevant across many departments and professions. Implementation should be coordinated by an executive leader (or equivalent role in organisations without executive boards) and supported by their designated senior leads for medical, nursing, midwifery, scientific and allied health professionals.

Explanation of identified safety issue:

Transfusion-associated circulatory overload (TACO) is defined as acute or worsening respiratory compromise and/or acute or worsening pulmonary oedema during or up to 12 hours after transfusion, with additional features including cardiovascular system changes not explained by the patient's underlying medical condition, evidence of fluid overload and a relevant biomarker. TACO is one of the most common causes of transfusion-related deaths in the UK and cases have increased substantially in recent years. Identifying risk factors for TACO prior to transfusion allows initiation of appropriate mitigating measures.¹ TACO deaths are potentially preventable. TACO can occur in any individual of any age, including elderly people, children, and neonates. The risk is increased by the following factors:

- cardiac dysfunction
- renal dysfunction
- low body weight
- hypoalbuminaemia
- pre-existing fluid overload
- high volume in relation to body weight
- severe chronic anaemia
- women with severe pre-eclampsia

Non-bleeding adult patients with severe chronic anaemia are particularly vulnerable to risk of TACO. Errors in prescription for blood components have been reported in children and can contribute to TACO. Pulmonary complications of transfusion within this group can be difficult to identify, particularly in neonates. There should be awareness of TACO as a potential cause of respiratory deterioration following transfusion in this group.^{2,3}

TACO risk reduction measures include:

- avoiding unnecessary transfusions
- single-unit transfusion or transfusing only the minimum number of units (or weight-adjusted red cell dose) needed to meet the haemoglobin (Hb) target (using red cell calculator⁴) and assessing response
- consideration of weight-adjusted red cell dosing for patients of low body weight (including children)
- avoiding transfusions in excess of recommended infusion rates
- administering a diuretic when appropriate
- monitor vital signs closely, including oxygen saturation

Further supporting information about TACO and this alert can be found in the supporting FAQ document.⁵

Actions required

Actions to be completed as soon as possible and no later than 4 October 2024:

1. Review and update **policies, procedures and processes** to ensure:
 - a. All transfusions are compliant with recommendations from British Society for Haematology (BSH),⁹ SHOT,¹ and NICE⁴
 - b. A TACO risk assessment is undertaken utilising the SHOT risk assessment tool⁶ prior to transfusions⁷
 - c. Appropriate mitigation measures are initiated for individuals at risk – see FAQ document⁵
 - d. Patients and carers should be informed of TACO as a significant potential complication of transfusion and likely symptoms, as part of complying with Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTG) consent for transfusion guidance⁸
 - e. Inclusion of guidance on timely management of TACO, including the use of diuretics, oxygen, and other supportive measures
 - f. Clear communications on discharge to patients and staff involved in the care of the patient about blood components and/or blood products administered and any complications such as TACO
 - g. Use of the structured TACO incident investigation tool¹¹ from SHOT
2. Review, update, and **implement training programmes** to include:
 - a. Use of TACO pre-transfusion risk assessment tool⁶
 - b. Appropriate use of mitigation measures – FAQ document⁵
 - c. Management of severe chronic anaemia in non-bleeding patients using minimal/single-unit transfusion support, and anaemia management with iron therapy where appropriate
 - d. Recognition and prompt management of TACO, importance of timely interventions and escalation of care as appropriate
 - e. Empowerment of clinical staff and biomedical scientists to question practices of prescribing/requesting blood components
 - f. A process for recording participation and identifying dates for re-training
 - g. Knowledge and awareness to report TACO cases locally, as well as to MHRA and SHOT by hospital transfusion teams
3. **Undertake regular audits** on the use of the TACO risk assessment tool for adult patients⁶, consent practices, management of chronic severe anaemia, avoidable transfusions, volume of red cell transfusion and communication of information at discharge to relevant teams involved in the care pathway including patients

"It is important to note that the TACO risk assessment tool has not been formally validated for paediatric age groups, but the risk factors are similar. Careful attention to appropriate volume and rate of transfusion is vital."

For further detail, resources and supporting materials see: <https://www.npsa.nhs.uk/about-us/alerts> and <https://www.shot.org>

For any enquiries about this alert contact: cp@npsa.nhs.uk or SHOT@nhs.uk

Paediatric TACO 2024



4 cases



~2% of TACO cases



1 resulted in mortality




1 resulted in major morbidity


Learning points

- TACO is likely under recognised in children. Although a formal TACO pre-transfusion risk assessment for children does not exist it is known from previous SHOT data that many of the same adult risk factors apply
- TACO can occur with small or appropriate volumes of component

Paediatric deaths by category and age group: 2010-2024



Paediatric challenges and unanswered questions



SHOT Transfusion Safety Standards

For a list of the organisations endorsing the SHOT Transfusion Safety Standards, please visit: [Transfusion Safety Standards - Serious Hazards of Transfusion](#)



1
Transfusion
safety



2
Transfusion
information
technology (IT)
and equipment



3
Supporting
staff to work
safely



4
Staff education
and training



5
Safety
culture



6
Patients as
safety partners



7
Haemovigilance
and risk
management



8
Governance



1. Transfusion safety



2. Transfusion information technology and equipment



3. Supporting staff to work safely



4. Staff education and training



5. Safety culture



6. Patients as safety partners



7. Haemovigilance and risk management



8. Governance



1. Transfusion safety



Anaemia
management



Performing TACO
pre-
administration
assessment



Management of
reactions




Monitoring
outcomes



Patient
awareness upon
discharge

Patient background and event

Haematology/oncology patient with a complex transfusion history.



Presence of multiple clinically significant red cell antibodies

Patient received 3 units of red cells that did not meet her documented specific requirements

Reasons attributed to this incident are:



Documentation

Requesting clinician failed to complete specific requirement of the request form.



Integration

Patient's historical record not showing on new upgraded LIM system



Oversight

Laboratory staff failed to check historical specific requirement flag from legacy LIM data

Incorrect Blood Component Transfused (IBCT) resources from SHOT

Specific requirements for patients - the essentials

SHOT

Welcome

This eLearning module will cover the different types of specific requirements in blood components that are required for certain patient groups

Key specific requirements in blood use addressed within this module are:

- Irradiated blood components
- Antigen negative and phenotype matched components
- Blood components for patients with haemoglobinopathies
- Cytomegalovirus screened negative components
- IgA deficient components
- HLA/NPA selected platelets
- Use of blood warmer during blood administration

SHOT Bite No. 20:
Incorrect blood component transfused – specific requirements not met errors

SHOT Serious Hazards of Transfusion

Introduction: Types of specific requirement (for components and administration)

Please see [SHOT Bite No. 19: Transfusion safety](#) for complete information on specific requirements. The information below is intended as a summary only. Your policies may also include additional patient groups.

- Irradiated components:** Required for a variety of conditions including: all granulocyte transfusions, intensive transfusions (IT) and subsequent neonatal transfusions, patients treated with purine analogues, Hodgkin's lymphoma, and pre- and post-haemopoietic stem cell transplants (HSCT).
Possible consequence of non-compliance: **Transfusion-associated graft-versus-host disease**
- Antigen negative K and D antigen negative red cells:** Required for individuals of childbearing potential who are negative for the antigen. Red cells should be antigen negative for any clinically significant corresponding antibody present (or previously detected) in patients plasma.
Possible consequence of non-compliance: **Maternal sensitisation leading to haemolytic disease of the fetus and newborn, or haemolytic transfusion reaction (HTR)**
- Phenotype matched:** Patients with haemoglobinopathies require red cells which are matched for Rh and F antigens.
Possible consequence of non-compliance: **Sensitisation, HTR, lower haemoglobin increments and increased frequency of transfusion**
- Cytomegalovirus (CMV) screened negative:** Required for all granulocyte transfusions in HSCT patients where the recipient is CMV negative, all IT and subsequent neonatal transfusions, and for elective transfusions in pregnancy.
Possible consequence of non-compliance: **CMV infection to the recipient or fetus**
- IgA deficient components:** Patients with a history of transfusion reactions caused by anti-IgA require plasma in citrate solution, washed red cells and IgA deficient fresh frozen plasma.
Possible consequence of non-compliance: **Allergic/anaphylactic reactions**
- HLA/NPA-matched:** Patients with proven anti-HLA or anti-NPA antibodies require platelets which are negative for the corresponding antigens.
Possible consequence of non-compliance: **Poor platelet increments and increased risk of bleeding**
- Blood warmer:** Some patients may have antibodies which only act at colder temperatures, for these patients a blood warmer is used to ensure the red cells are at the right temperature as they are transfused.
Possible consequence of non-compliance: **Blood clots and destruction of transfused red cells**

SHOT data 2016-2020

Fig. 1 shows the number of incorrect blood component transfused-specific requirements not met (IBCT-SRNM) errors 2016-2020. 1171167 (10.0%) cases involved paediatric patients. No deaths occurred due to IBCT-SRNM during this period, but 12 cases of major morbidity were directly caused (Fig. 2). Most clinical errors are failure to request irradiated or CMV screened components and most laboratory errors are failure to complete testing prior to issue, inappropriate use of electronic issue or providing the incorrect phenotype.

Fig. 2. Major morbidity caused by IBCT-SRNM 2016-2020 (n=12)

Category	Percentage
Haemolytic transfusion reaction	1, 8.3%
Sensitisation to K antigen	11, 91.7%



June 2022



Remember Positive Patient Identification is essential



Human Factors resources developed by SHOT



‘My Transfusion’ patient app

- For adult patients receiving transfusion and their carers/relatives
- Covers the transfusion journey, transfusion risks, benefits and alternatives for patients
- Based on current national guidelines
- Created with insights from patients and healthcare professionals



What can you do?

Report any errors or concerns to
Transfusion Practitioner

Ensure a safe environment for transfusions

Be a champion for transfusion safety

Suggested activities



Spend some time with a haemovigilance reporter when they are completing a SHOT report



Attend a hospital transfusion committee meeting



Attend an investigation meeting




Review your hospital transfusion policies



Carry out a consent review and the use of pre-transfusion checklist / SRNM



Carry out a review of your Trust's SHOT reports




Take away messages

- Take some time to read the SHOT data
- Remember TACO pre-transfusion risk assessment, especially on our high-risk vulnerable patients
- Correct prescribing of blood components for infants and children is vital
- Make every transfusion count



SHOT App



Download on the
App Store



GET IT ON
Google Play

Acknowledgements

- **The reporters and hospital staff who share their incidents**
- The SHOT Steering Group and Working Expert Group members
- MHRA haemovigilance team
- The UK Forum for funding

For further information visit: www.shotuk.org



<https://stock.adobe.com/uk/>